Fundraising Fox5AM Ventures — 2016 Investments
7 investments dated 2016 · listed companies and verified rows first · show all
IDEAYA is a precision medicine oncology company developing first-in-class targeted therapies and rational drug combinations for molecularly defined, hard-to-treat cancers.
BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US
Paul Stone(Executive Officer)inYujiro S. Hata(President, Chief Executive Officer and Director)
BoardTimothy Shannon(Director)inJohn Diekman(Director)inTerry Rosen(Director)Jeffrey Stein(Director)
Board seatJohn D. DiekmanBrian Daniels· per SEC Form D
Co-investorsCanaan PartnersGV (Google Ventures)Nextech InvestRoche Venture FundBiotechnology Value FundWuXi Healthcare Ventures
Pioneering the development of prescription digital therapeutics.
HealthtechBoston, US
Corey McCann(Executive Officer, Director)inAntoun Nabhan(Executive Officer)Christopher Guiffre(Executive Officer)
BoardAndrew Schwab(Director)inTimothy Petersen(Director)inZack Lynch(Director)in
Board seatAndrew J. Schwab· per SEC Form D · $20.4M raise · filed Feb 2016
Co-investorsJAZZ Venture PartnersArboretum VenturesGeneral CatalystOCA VenturesSeyen CapitalSoftBank Group+2 more
.png)
South San Francisco biotech engineering commensal gut bacteria into controllable live therapeutics for chronic diseases.
Daly City, US
Weston Whitaker(Executive Officer, Director, Promoter)William DeLoache(Director)Samuel Smits(Director)
BoardElizabeth Stanley(Director)
Co-investorsAlta PartnersCerity Partners VenturesColorcon VenturesAlexandriaDCVC (Data Collective)DCVC Bio+2 more
Soteria provides cybersecurity advisory services and solutions, including managed detection and response (MDR), virtual CISO support, domain monitoring, and Microsoft 365 risk management.
CybersecurityEnterprise SoftwareSaaSCharleston, US
Glenn Starkman(Co-Founder)inCHRISTOPHER O'ROURKE(Executive Officer)in
Co-investorsCheckmate Capital Group LLCRoche Venture Fund
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.